Compare Amphastar Pharmaceuticals Inc (AMPH) vs Herbalife Nutrition Ltd (HLF) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Herbalife (HLF) trades at $13.15, up 1.94% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains stable revenue around $5B annually with improving debt metrics, though negative shareholder equity remains a concern. Recent Q1 2026 earnings beat expectations with EPS of $0.64 versus $0.607 expected, supported by strong international growth and successful $1.45B debt refinancing completed in April 2026.

HLF presents a value opportunity with low P/E (5.77) and P/S (0.27) ratios, but faces significant leverage risks and competitive pressures. Analyst sentiment leans bullish (58% buy ratings) despite technical weakness, with the stock's direction likely dependent on Q2 2026 results announcement scheduled for August 5, 2026.